FDA Launches Expedited Investigational New Drug Pilot Program to Accelerate Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced the final design of its Expedited Investigational New Drug (IND) Pilot program. This initiative aims to accelerate clinical trial timelines and reduce regulatory hurdles, a core priority for the Trump Administration to maintain American leadership in global medical innovation. The pilot will partner drug companies with qualified research institutions to streamline the development of IND applications, with the goal of significantly shortening the time from drug identification to first-in-human clinical trials.